MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on …
M Lu, C Hu, F Wu, L Shu, Y Pan, X Liu, P Liu, F Ma… - Lung Cancer, 2020 - Elsevier
Background Currently, the main treatment for non-small cell lung cancer (NSCLC) is surgery
and chemotherapy. Although major progress has been made in targeted treatment and …
and chemotherapy. Although major progress has been made in targeted treatment and …
MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on …
M Lu, C Hu, F Wu, L Shu, Y Pan… - Lung cancer …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Currently, the main treatment for non-small cell lung cancer (NSCLC) is surgery
and chemotherapy. Although major progress has been made in targeted treatment and …
and chemotherapy. Although major progress has been made in targeted treatment and …
MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on …
M Lu, C Hu, F Wu, L Shu, Y Pan, X Liu… - Lung Cancer …, 2020 - europepmc.org
Background Currently, the main treatment for non-small cell lung cancer (NSCLC) is surgery
and chemotherapy. Although major progress has been made in targeted treatment and …
and chemotherapy. Although major progress has been made in targeted treatment and …
MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on …
M Lu, C Hu, F Wu, L Shu, Y Pan, X Liu, P Liu… - Lung …, 2020 - lungcancerjournal.info
Background Currently, the main treatment for non-small cell lung cancer (NSCLC) is surgery
and chemotherapy. Although major progress has been made in targeted treatment and …
and chemotherapy. Although major progress has been made in targeted treatment and …